Mergers & Acquisitions ·
Crinetics Pharmaceuticals reports that the Hart-Scott-Rodino waiting period for its proposed merger with Vertex…
CRNXCrinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals reports that the Hart-Scott-Rodino waiting period for its proposed merger with Vertex Pharmaceuticals expired on August 12, 2026. Additionally, antitrust approvals from Austria and Germany have been received as of August 13, 2026, while Australian approval remains pending until a waiting period expires on August 27, 2026. The transaction is contingent upon shareholder adoption at a special meeting scheduled for August 28, 2026, with closing expected in early September 2026. Crinetics Pharmaceuticals operates in the biotechnology industry and develops therapies for rare diseases.